Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
clinical trials
europe top stories
4
×
fda
life sciences
national blog main
europe blog main
national
national top stories
san francisco top stories
boston blog main
boston top stories
new york top stories
san francisco blog main
abaloparatide
abbvie
alkermes
allergan
amgen
arena pharmaceuticals
billy dunn
biogen
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
drug prices
drug pricing
eisai
eli lilly
europe
european commission
evrysdi
felipe jain
gene therapy
What
drug
4
×
medicine
4
×
fda
marketing
patients
weight
alkermes
amgen
amgen’s
antipsychotic
approval
approved
atrophy
benefits
cancer
carries
caveats
commonly
daily
designed
developed
effect
eisai
europe
european
evrysdi
favor
flags
friday
gain
green
heart
higher
home
incidence
intended
lights
liquid
lorcaserin
loss
Language
unset
Current search:
medicine
×
biotech
×
drug
×
" europe top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning